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 We investigated the clinical efficacy of low-dose and 
long-term 14-member macrolide therapy for 33 patients 
with Palomoplantar Pustulosis (PPP) most of whom showed 
a poor clinical response to topical corticosteroid and/or 
photo chemotherapy. After 4-12 weeks treatment with oral 
erythromycin (EM; 600mg/day) or clarithromycin (CAM ; 200 
mg/day) in combination with previously used corticosteroid oint-
ment, clinical evaluation was made on the basis of clinical score. 
Results are as follows: marked improvement ; 19 patients 
(57.6%), moderate improvement ; 7 patients, no clinical re-
sponse ; 7 patients. There was no serious side effect during 
the observation period. In vitro studies suggest that CAM, 
a 14-member macrolide, significantly down-regulated IL-8 
production by keratinocytes stimulated with combination of
IFNγ and　 TNFα 　or　 staphylococcal-superantigen(SEB)and
IFNγ 　 both　 at　 protein　 and　 mRNA　 levels.
 We would like to propose that low-dose and long-term 
14-member macrolide therapy is effective and an alternate 
therapy for PPP with poor response to ordinal dermatological 
therapy of which mechanism is presumable inhibition of 
neutrophil chemotaxisis by inhibiting IL-8 production by 
keratinocytes.
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Introduction
 "Low-dose and long-term" 14-member macrolide therapy 
has been reported as effective in diffuse panbronchiolitis 
(DPB)'. The prognosis of patients with DPB was very
Address Correspondence: Yoshitaka Matsunaga, M.D. 
Department of Dermatology, Nagasaki University School of 
Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan 
TEL: +81-95-849-7333 FAX: +81-95-849-7335
poor, especially in cases with Pseudomonas aeruginosa 
infection in the past. However in 1987, Kudoh et al. re-
ported that the long-term and low-dose oral admini-
stration of EM was effective in DPB2. Although its pre-
cise mechanisms are not yet clear, many investigators 
suggest that EM and other 14-member macrolide 
might act as an anti-inflammatory agent rather than 
an anti-bactericidal one. Recently the study of its in-
hibitory actions on various neutrophilic inflammations 
has been developed rapidly and become of special 
interest'-'. It is reported that EM inhibits IL-8 produc-
tion by cultured human bronchial epithelial cells'. 
 IL-8 is one of the major chemotactic factor for 
neutrophils, then it is suggested that EM inhibits 
neutrophil infiltration by suppressing IL-8 production. 
 Palmoplantar pustulosis (PPP) is a common chronic 
skin disease characterized by sterile intraepidermal 
pustules and erythematous, scaly skin. In addition, 
PPP frequently recurs and occasionally shows some 
resistance to usual therapies such as topical corticosteroid 
or photochemotherapy. In the histopathological feature 
of PPP, many neutrophils infiltrate to pustules and 
upper dermis. And immunohistological study, lesional 
keratinocytes expressed IL-8. Therefore it is considered 
that neutrophils and IL-8 generated by keratinocytes play 
important roles in the etiology of PPP'. 
 Focal infection such as chronic tonsillitis or dental 
caries play some role in the induction of PPP, since 
PPP occasionally improves following the treatment 
with them. Although the mechanisms still remain un-
clear, bacterial superantigen released in the circulation 
from focal infection site is suggested one possible can-
didate for induction of PPP. Superantigen binds to 
MHC class II molecule on antigen presenting cells or 
keratinocytes and induces inflammatory response by 
activating T cells or keratinocytes18. 
 Therefore, in this study, we investigate the clinical 
efficacy of 14-member macrolide for patients with PPP
most of whom showed poor clinical response to ordi-
nal topical corticosteroid or PUVA therapy. The action 
of CAM on IL-8 production by kerationcytes was ex-
amined using ELISA and RT-PCR method.
Materials and Methods
Patient population 
 Thirty three patients with PPP consisting of 7 males 
and 26 females (year range 23-73) were enrolled in 
this study after informed consent. The patients' pro-
files were summarized in table 1. Thirty one out of 33 
cases showed a poor clinical response to topical 
corticosteroid ointment at the start of macrolide ther-
apy. EM (600mg/day) was started on 21 cases and 
CAM (200mg /day) was started on 12 cases. Basal 
ointment which had been applied to the lesional skin 
was unchanged during the macrolide therapy. 
 After 4-12 weeks, clinical effects were evaluated on 
the basis of clinical score : 2 + ; marked improvement 
with more than 50% reduction of pustules and clear-
ance of erythema, 1 + ; moderate improvement of 
erythema with less than 50% reductions of pustule, 
0 ;no clinical response.
Reagents and antibody 
 CAM was provided by Taishyo Pharmaceutical Co. 
Ltd, Japan. For in vitro experiment, CAM powder was 
dissolved in dimethyl sulphoxide (DMSO ; SIGMA, St. 
Louis, USA ) and thereafter diluted in culture medium. 
Recombinant human tumor necrosis factor- a (TNF a ) 
and recombinant human interferon-gamma (IFN y ) 
were obtained from Genzyme (Cambridge, USA). 
Staphylococcal enterotoxin B (SEB) was purchased 
from SIGMA (St. Louis, USA). Rabbit anti-human IL-8 
polyclonal purified antibody ENDOGEN (Woburn, 
USA) was used for immunohistochemistry.
Immunohistochemistry 
 With the informed consent of the patients, biopsies 
were taken from the lesion of PPP. 'Frozen 6-,u m sec-
tions fixed in acetone were initially treated with 0.3% 
H202/methanol for blocking of internal peroxidase, and 
then covered with 10% normal goat serum in PBS for 
lh at room temperature. After incubation with anti-
human IL-8 antibody (1: 200 in 5% bovine serum al-
bumin in PBS (BSA/PBS) or normal rabbit serum (1: 
500 in BSA /PBS) overnight at 41C, sections were 
stained with DAKO LSAB® 2 Kit according to the
method by manufacturer. For nucleus stain, Mayer's 
hematoxylin was used.
Cell culture 
 Primary normal human keratinocytes were pur-
chased from NORMAL HUMAN CELL SYSTEMS 
(Sanko Junyaku Co. LTD, Japan). These were pooled 
cells derived from neonatal donors. Cells were grown 
in culture using a defined KGM (CC-31 11, Sanko 
Junyaku Co. LTD, Japan) in a humidified incubator 
controlled at 371C and having an atmosphere of 5 % 
CO, After the third passage, the cells seeded at 1 X 105 
cells/cm' in 24 wells culture cluster (Corning, NY). At 
confluent state, cells were cultured in serum-free me-
dium, KBM (CC-3101, Sanko Junyaku Co. LTD, Japan) 
for 24h. After pre-incubation with replaced fresh KBM 
in the presence of CAM (0-1000ng / ml) for lh, 
keratinocytes were further cultured with TNF a (250 
U/ml) and IFN y (250U/ml) or SEB (50ng/ml) and 
IFN y (250U/ml) for 24h.
IL-8 determination by ELISA 
 IL-8 concentrations in keratinocyte culture supernatants 
were measured using enzyme-linked immunosorbent assay 
(ELISA) kit (Genzyme, Cambridge, USA). A standard 
curve was produced using known concentration of the 
recombinant human IL-8 provided in the kit. The con-
centration of IL-8 in the supernatants was determined 
from the standard curve.
RT-PCR analysis of IL-8 mRNA expression 
 Total RNA was extracted from the cultured 
keratinocytes by RNeasy Mini Kit (QIAGEN GmbH, 
Germany). cDNA synthesis was performed by 
Superscript II (Gibco BRL, Rockville, MD) according 
to the method by manufacturer. In short, the cycle 
condition is 94°C for 2 min., followed 94°C for 60 sec., 
56°C for 60 sec. and 72°C for 90 sec. and 721'C for 90 
sec : 30 cycles for IL-8, 25 cycles for /9 -actin by 
Takara Ex Tag TM (Takara Shuzo, Shiga, Japan). 
/9 -actin (Clontech, Palo Alto, CA) was used in this 
study. Synthetic oligonucleotides of human IL-8 were 
used (Amersham Pharmacia Biotech) as 5' IL-8 primer : 
ATGACTTCCAAGCTGGCCGTGGCT, and as 3' IL-8 
primer : TCTCAGCCCTCTTCAAAAACTTCTC10 
 We analyzed mRNA expression of IL-8 by scanning 
densitometry and expressed in relation to 9 -actin 
scanning density using the NIH image program.
Statistics 
  The result were analyzed by student's t-test. Each 
value represents the mean ± SD (n=3) .*p<0.05
 There was no serious side effect except one case 
with transient abdominal discomfort during the obser-
vation period.
Results
Macrolide therapy for PPP 
 Open trial of macrolide for PPP was evaluated at 4-
12 weeks after the therapy. Results are as follows: 
marked improvement ; 19 patients (57.6%) as shown 
in Fig. 1 and Fig. 2, moderate improvement ; 7 patients, 
no clinical response ; 7 patients (Table 2). On the basis 
of clinicians' and patients' assessment, more than 75% 
of the patients responded to macrolide therapy . Among 
the responded group, no recurrence of PPP was observed 
in 4 cases for more than three months.
Inhibitory effect of CAM on cytokine-induced IL-8 
production by keratinocytes. 
  Several reports have shown that keratinocyte is one 
of the source of IL-8 in the human skin"'. Therefore, 
we investigated immunohistopathological analysis and 
revealed the over expression of IL-8 on the lesional 
keratinocytes of PPP (Fig. 3). In addition, we studied 
whether CAM affects production of IL-8 by cytokine 
stimulated-keratinocytes. As shown in Fig. 4, CAM sig-
nificantly down regulated IL-8 production by TNF a 
and IFN y -stimulated cultured human keratinocytes in 
a dose-dependent manner. 
 CAM also down-regulated IL-8 mRNA expression in 
keratinocytes ( Fig. 5 and Fig. 6).
Fig. 1. Case 1 : (a), (b) before treatment and (c), (d) 6 weeks after treatment. 
      In this case, pustules and erythema were almost disappeared after treatment.
Inhibitory effect of CAM on superantigen-induced IL-8 
production by keratinocytes. 
 It has been reported that focal infections such as 
chronic tonsillitis or caries frequently exasperate PPP 
and treatment of these bacterial infection clearly re-
solves the PPP".
 Therefore we analyzed the effect of superantigen-
induced IL-8 production by cultured human keratinocytes. 
As shown in Fig. 7, CAM significantly down-regulated IL-8 
production by SEB and IFN y -stimulated cultured human 
keratinocytes in a dose-dependent manner. And CAM also 
down-regulated IL-8 mRNA expression in keratinocytes 
(Fig. 8 and Fig. 9).
Fig. 2. (a), (b) before treatment and (c), (d) 8 weeks after treatment.
Table 1. Patients profiles enrolled in this study.
                   Previous treatment Focal infection Treatment 
Sex No. Steroid ointment non (+) (-) EM(600mg/day) CAM(200mg/day) 
M 7 7 0 3 4 6 1 
 F 26 24 2 4 22 15 11 
Total 33 31 2 7 26 21 12
Focal infection; tonsillitis, caries EM; erythromycin CAM; clarithromycin
Table 2. Clinical response of palmoplantar pustulosis to oral macrolide.
                            Result 
Observation period 2+ 1+ 0 
    1-4W 7 4 4
    4-8W 4 1 3
    8W< 8 2 0
    Total 19 (57.6%) 7 (21.2%) 7(21.2%)
Fig 4. Inhibitory effect of CAM on cytokine-induced IL-8 pro-
      duction by keratinocytes. Each value represents the 
     mean ± SD (n=3) . *p<0.05
Fig 3. Immunohistopathological analysis of PPP skin le-
     sions . (a) Control serum and (b) anti IL-8 anti-
     body.
Fig 5. Inhibitory effect of CAM on cytokine-induced IL-8 
      mRNA expression in keratinocytes.
Fig 8. Inhibitory effect of CAM on superantigen-induced IL-8 
     mRNA expression in keratinocytes.
Fig 6. The values were determined by scanning densitometry 
     and expressed cytokine-induced IL-8 mRNA in relation 
     to 9-actin scanning density with NIH image.
Fig 9. The values determined by NIH image showed that in-
     hibitory effect of CAM on superantigen-induced IL-8
     mRNA expression.
Fig 7. Inhibitory effect of CAM on superantigen-induced IL-8 
      production by keratinocytes. Each value represents the 
     mean ± SD (n=3). *p<0.05
Discussion
 Low-dose and long-term oral macrolide therapy signifi-
cantly improved the refractory PPP which had been 
treated with potent topical corticosteroid with unfavorable 
results. More than 75% of the patients responded to 
macrolide therapy. Clinical effect was objectively recog-
nized shortly after the start of the therapy (1-2 weeks) 
and patients' evaluations were favorable after the therapy 
(4-12 weeks). Four patients did not recur even 3 months 
after the therapy. 
 Macrolide therapy applied in this communication 
was initially studied in the patients with diffuse 
panbronchiolitis (DPB) with favorable clinical effect'. 
DPB is characterized by chronic inflammation, local-
ized predominantly in the respiratory bronchioles, with 
infiltration of inflammatory cells'. The clinical features of
DPB are chronic or continuous pulmonary infection and 
inflammation. The prognosis of patients with DPB was 
very poor, especially in cases with P.aeruginosa infection 
in the past. In 1987, Kudoh et al. reported that the long-
term and low-dose oral administration of EM was effective 
in chronic lower respiratory tract diseases, including DP 
B2. Its precise mechanisms are not yet clear, but many 
investigators suggest that EM might act as an anti-
inflammatory agent rather than an antibactericidal one". 
And the study of its inhibitory actions on neutrophilic in-
flammation has developed rapidly and become of special 
interest'. It is reported that EM inhibits IL-8 production 
by cultured human bronchial epithelial cells'. IL-8 is one 
of the major chemotactic factor for neutrophils, then it is 
suggested that EM inhibits neutrophils infiltration by sup-
pressing IL-8 production. Similar efficacy was observed 
with other 14-member macrolide drug , CAM as reported 
in this communication.
 PPP is a common chronic skin disease, which occasion-
ally shows poor response to usual dermatological therapy 
such as topical corticosteroid or photochemotherapy". 
Acute exacerbation after focal infection such as tonsil-
litis or periodontal diseases is occasionally observed in 
a similar manner to acute generalized pustular bacterid15. 
PPP is characterized by sterile intraepidermal pustules 
with neutrophilic infiltration which is considered to 
play an important role in the etiology of PPP". And it is 
reported that intercellular epidermal IL-8 immunolabeling 
was regularly detected in lesional biopsies in PPP, but not 
in healthy subjects or non-lesional skin in PPP". Therefore 
it is considered that neutrophils and IL-8 generated by 
keratinocytes play important roles in the pathogenesis of 
PPP9. 
 These clinical and histopathological findings suggest 
that bacterial factors might be involved in activation 
of neutrophis through affecting immune system. Bacterial 
superantigens such as streptococcal pyrogenic exotoxin A 
(SPE A), or SEB activate T cells resulting in produc-
tion of neutrophil activating cytokines". In addition, 
superantigens induce TNF a or IL-1 a by human 
keratinocytes in the presence" or absence of MHC 
class II molecule expression". In this study, we showed 
that SEB also induces IL-8 production by keratinocytes. 
Involvement of other neutrophilic chemokines such as 
MIP1 a, MIP1 9, or NAP2 should be clarified in the fu-
ture study. 
 Our results showed that 14-member macrolide sig-
nificantly down-regulated the IL-8 production by 
cytokine or SEB stimulated keratinocytes might ex-
plain the one aspect of clinical effect of macrolide 
therapy or refractory PPP. Although colchicine20 or 
clofazimine21 have been known to be effective for PPP 
through inhibition of chemotactic or bactericidal activ-
ity of neutrophils, these drugs are not widely used for 
their serious side effects. 
 Taken together, 14-member macrolide therapy would 
be more safe and effective therapy for PPP especially 
for the refractory and uncontrolled patients with usual 
dermatological therapies.
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